Target Gene/Pathway(薬物標的遺伝子/パスウェイリスト)

e.g. "Sirolimus", "アダリムマブ", "MAP2K"

ABCDEFGH I JKLMNOPQRSTUVWXYZother

33 / 286 pathways

No. KEGG PATHWAY   💬 Info on mouse-over
On map, Yellow: Drug target, Red: All disease-related
KEGG GENES
💬 Info on mouse-over
KEGG DRUG
💬 Info on mouse-over
DrugBank 指定難病告示番号
💬 Info on mouse-over
1 Adipocytokine signaling pathway 💬
1件: JAK2 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
2 AGE-RAGE signaling pathway in diabetic complications 💬
1件: JAK2 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
3 Chemokine signaling pathway 💬
1件: JAK2 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
4 Cholinergic synapse 💬
1件: JAK2 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
5 Coronavirus disease - COVID-19 💬
1件: JAK1 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
6 EGFR tyrosine kinase inhibitor resistance 💬
2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
7 Epstein-Barr virus infection 💬
1件: JAK1 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
8 Growth hormone synthesis, secretion and action 💬
1件: JAK2 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
9 Hepatitis B 💬
2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
10 Hepatitis C 💬
1件: JAK1 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
11 Herpes simplex virus 1 infection 💬
2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
12 Human cytomegalovirus infection 💬
1件: JAK1 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
13 Human papillomavirus infection 💬
1件: JAK1 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
14 Human T-cell leukemia virus 1 infection 💬
1件: JAK1 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
15 Influenza A 💬
2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
16 JAK-STAT signaling pathway 💬
2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
17 Kaposi sarcoma-associated herpesvirus infection 💬
2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
18 Leishmaniasis 💬
2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
19 Measles 💬
1件: JAK1 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
20 Necroptosis 💬
2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
21 NOD-like receptor signaling pathway 💬
1件: JAK1 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
22 Osteoclast differentiation 💬
1件: JAK1 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
23 Pancreatic cancer 💬
1件: JAK1 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
24 Pathways in cancer 💬
2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
25 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
26 PI3K-Akt signaling pathway 💬
2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
27 Prolactin signaling pathway 💬
1件: JAK2 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
28 Signaling pathways regulating pluripotency of stem cells 💬
2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
29 Th1 and Th2 cell differentiation 💬
2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
30 Th17 cell differentiation 💬
2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
31 Toxoplasmosis 💬
2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
32 Tuberculosis 💬
2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
33 Viral carcinogenesis 💬
1件: JAK1 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬